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David J Klumpp4, Anthony J Schaeffer4, Karl J Kreder5, Dedra Buchwald6, Gerald L Andriole7, M Scott Lucia8,
J Richard Landis9, Daniel J Clauw10 and The MAPP Research Network Study GroupAbstract
Urologic chronic pelvic pain syndrome (UCPPS) may be defined to include interstitial cystitis/bladder pain
syndrome (IC/BPS) and chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). The hallmark symptom of
UCPPS is chronic pain in the pelvis, urogenital floor, or external genitalia often accompanied by lower urinary tract
symptoms. Despite numerous past basic and clinical research studies there is no broadly identifiable organ-specific
pathology or understanding of etiology or risk factors for UCPPS, and diagnosis relies primarily on patient reported
symptoms. In addition, there are no generally effective therapies. Recent findings have, however, revealed associations
between UCPPS and “centralized” chronic pain disorders, suggesting UCPPS may represent a local manifestation of
more widespread pathology in some patients. Here, we describe a new and novel effort initiated by the National
Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the U.S. National Institutes of Health (NIH) to address
the many long standing questions regarding UCPPS, the Multidisciplinary Approach to the Study of Chronic Pelvic
Pain (MAPP) Research Network. The MAPP Network approaches UCPPS in a systemic manner, in which the interplay
between the genitourinary system and other physiological systems is emphasized. The network’s study design expands
beyond previous research, which has primarily focused on urologic organs and tissues, to utilize integrated approaches
to define patient phenotypes, identify clinically-relevant subgroups, and better understand treated natural history and
pathophysiology. Thus, the MAPP Network provides an unprecedented, multi-layered characterization of UCPPS.
Knowledge gained is expected to provide important insights into underlying pathophysiology, a foundation for better
segmenting patients for future clinical trials, and ultimately translation into improved clinical management. In addition,
the MAPP Network’s integrated multi-disciplinary research approach may serve as a model for studies of urologic and
non-urologic disorders that have proven refractory to past basic and clinical study.
Trial registration: ClinicalTrials.gov identifier: NCT01098279 “Chronic Pelvic Pain Study of Individuals with Diagnoses or
Symptoms of Interstitial Cystitis and/or Chronic Prostatitis (MAPP-EP)”.
Keywords: Urological chronic pelvic pain syndromes, Interstitial cystitis, Chronic prostatitis, Translational research,
Multi-disciplinaryBackground
Urologic chronic pelvic pain syndrome (UCPPS) encom-
passes two highly prevalent non-malignant urologic disor-
ders, interstitial cystitis/bladder pain syndrome (IC/BPS)
and chronic prostatitis/chronic pelvic pain syndrome (CP/
CPPS). UCPPS is primarily characterized by chronic and
often debilitating pain in the pelvic region and/or genitalia* Correspondence: qclemens@med.umich.edu
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unless otherwise stated.and typically a spectrum of defects in bladder and lower
urinary tract function [1,2].
Numerous studies have been conducted over the past
two decades to define the pathophysiology and natural
history of UCPPS and to examine the efficacy of therapies.
Many of those studies were supported by the National
Institute of Diabetes and Digestive and Kidney Diseases
(NIDDK) of the U.S. National Institutes of Health (NIH).
The first NIDDK-sponsored pelvic pain clinical research
network, the Interstitial Cystitis Database study (ICDB)
was initiated in 1991 [3]. This five-year prospective cohortal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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acterized them across demographic and clinical character-
istics, including bladder biopsy [4]. The Interstitial Cystitis
Clinical Trials Group (ICCTG) was subsequently estab-
lished to conduct randomized clinical trials beginning in
1996 [5-9]. In 2003, this group became the Interstitial
Cystitis Collaborative Research Network (ICCRN) and
carried out additional randomized clinical trials [10-12]. In
1998, the Chronic Prostatitis Cohort (CPC) study began
to prospectively collect patient data to systematically exam-
ine the demographics, clinical characteristics and natural
history of CP/CPPS [13]. The NIDDK subsequently initi-
ated the Chronic Prostatitis Collaborative Research Net-
work (CPCRN) which performed clinical trials for CP/
CPPS [14-17]. Results from these clinical research studies
failed to identify definitive risk factors or generally effective
treatments, with the exception of a single study suggesting
that myofascial physical therapy might be effective in IC/
BPS [18]. The NIDDK-supported Boston Area Commu-
nity Health (BACH) Survey [19-21] and the RAND IC
Epidemiology (RICE) Study [22,23] provided estimates on
the prevalence of IC-related symptoms for both men and
women, as well as an expanded understanding of symptom
morbidity. In addition to these clinical and epidemiological
studies, many basic research efforts were developed to de-
scribe pathophysiology at the cellular level, including in vivo
studies of model systems. However, no consensus agreement
has been achieved on an underlying etiology for UCPPS,
though co-occurrence of UCPPS with other chronic non-
urologic pain syndromes has been revealed [24-30].
In light of the limitations of previous studies and re-
sults showing potential associations between UCPPS
and other chronic pain conditions, the NIDDK proposes
that the traditional bladder and prostate centered focus
of UCPPS research be broadened to a systemic view of
disease in which the interplay between the genitouri-
nary system and other physiological systems (e.g., the
central nervous system), is highlighted. In addition, it is
suggested that studies of UCPPS would benefit from in-
corporating broad approaches involving a diversity of uro-
logic and non-urologic disciplines to promote a more
comprehensive characterization of patient phenotype.
These concepts, as well as recommendations solicited
from the scientific community [31], prompted the NIDDK
to initiate a new research program for the study of UCPPS,
the Multidisciplinary Approach to the Study of Chronic
Pelvic Pain (MAPP) Research Network. Since its inception
in 2008, the MAPP Research Network has adopted a
highly collaborative and integrated research strategy
that incorporates new and novel approaches conducted
by investigators representing traditional urologic disci-
plines and broad non-urologic expertise, including ex-
perts in pain research, neurobiology and neuroimaging,
infectious disease, biomarker discovery, animal modeling,epidemiology, psychology, immunology, among many
others. The overarching goal of the MAPP Research
Network is to provide findings useful for designing fu-
ture clinical trials and ultimately to improve clinical
management for UCPPS patients. Importantly, the de-
sign and goals of the MAPP Network are complemen-
tary to other large phenotyping efforts for non-urologic
pain conditions being conducted, such as the OPPERA
study [32].
The MAPP Research Network includes six Discovery
Sites and several specialized sub-sites that conduct mul-
tiple, collaborative Trans-MAPP (i.e., across sites) stud-
ies, as well as a number of single-site studies, and two
specialized Cores (see Acknowledgement for complete list-
ing of MAPP Network Sites and affiliated personnel). The
Data Coordination Core (DCC) serves as the central site
for data acquisition and storage; provides bio-statistical ana-
lyses for all studies; and promotes network-wide quality as-
surance. The DCC also provides administrative support,
including development and maintenance of a public web-
site (http://www.mappnetwork.org/). The Tissue Analysis
and Technology Core (TATC) monitors biosample collec-
tion and provides sample banking, annotation, and distribu-
tion services.
The MAPP Research Network is currently conducting
complementary basic, translational, and clinical science
studies to investigate questions of significant clinical rele-
vance and adopts the view that UCPPS potentially involves
significant systemic contributions. The primary scientific
protocol is a prospective observational study of the treated
natural history UCPPS, the Trans-MAPP Epidemiology/
Phenotyping (EP) Study. A full description of the central
Trans-MAPP EP Study and the complement of urologic
and non-urologic measures employed are described in the
companion report by Landis et al. [33]. In addition to the
extensive phenotyping, the Trans-MAPP EP Study also
provide a source of highly characterized participants for
further phenotyping through other integrated network
protocols. Assembled network working groups develop
and conduct complementary Trans-MAPP studies that
broadly address potential contributions of various physio-
logical systems and hypotheses of underlying etiology,
pathophysiology, risk, and relationships between UCPPS
and commonly associated non-urologic syndromes. These
include structural and functional assessments of the cen-
tral nervous system; efforts to uncover potential contribu-
tions of infectious agents to etiology; discovery efforts to
identify new biological markers; extensive characteriza-
tions of symptom variation (e.g., flares); and efforts to
develop new and more informative patient reported out-
come measures. The network is also engaged in collab-
orative research to establish and assess animal models
validated for the presence of clinically-relevant pheno-
types, thus allowing for improved translation between
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vide comprehensive, state-of-the-art phenotyping data
which will set the standard for future UCPPS research.
Results from the MAPP study can be integrated with
other, more clinically focused phenotyping efforts (such
as the UPOINT system [34,35]) to better define the
‘minimal data set’ required to provide optimal patient
care for UCPPS patients.
Within the MAPP Research Network all clinical Trans-
MAPP protocols and site-specific efforts, which primarily
serve to pilot test ideas complementary to the collabora-
tive protocols, are highly integrated through their use of
shared patients and controls evaluated through standard
phenotyping; common biological samples; and a standard-
ized data collection, storage, and analysis strategy. In
addition, neuroimaging study parameters are standard-
ized across sites and scan data is centrally managed by
the University of California at Los Angeles (UCLA)
Center for Neurobiology of Stress (painrepository.org),
in close collaboration with UCLA-Laboratory of Neuro-
imaging (LONI), which has extensive experience in the
collection, storage and analysis of large multi-site MRI
data sets (loni.usc.edu). In this way diverse findings
across protocols may be integrated to allow a detailed
characterization of a single UCPPS patient or patient
sub-groups. Importantly, these efforts are also generat-
ing a unique national resource of highly detailed longi-
tudinal clinical and epidemiological data associated with
data from additional, integrated phenotyping studies
and linked biological samples, for future use by the
wider research community through the NIDDK Data
and Sample Repositories (http://www3.niddk.nih.gov/
researchprograms/repositories/).
Conclusions
UCPPS research is clearly at a cross-road in which the
traditional basic and clinical scientific strategies are being
re-evaluated in light of evolving ideas of UCPPS and rec-
ognition of the limitations of previous study designs. The
MAPP Research Network was created to address these
challenges. Advances from network efforts are expected to
provide a more comprehensive understanding of UCPPS
pathophysiology, identify clinically relevant patient sub-
groups, inform the design of future clinical trials, and ul-
timately improve clinical care. The unique organization
and approach of the MAPP Network may also provide a
blueprint for multi-site, multi-disciplinary research in the
broader pain field, as well as for those disciplines address-
ing other disorders with ill-defined pathophysiology.
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